Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | THRB | P10828 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25347981 | 0.93 | TP53 (0.88) | TP53LMNAMAPTALDH1A1KMT2A | |
| SCHEMBL25349392 | 0.93 | TP53 (0.88) | TP53LMNAMAPTALDH1A1KMT2A | |
| SCHEMBL18545997 | 0.87 | HSP90AA1 (0.79) | TP53LMNAMAPTALDH1A1KMT2A | |
| SCHEMBL9478142 | 0.84 | TP53 (0.73) | TP53LMNAMAPTALDH1A1HSP90AA1 | |
| SCHEMBL25348940 | 0.82 | TP53 (0.74) | TP53LMNAMAPTALDH1A1KMT2A | |
| SCHEMBL25349918 | 0.82 | TP53 (0.69) | TP53LMNAMAPTALDH1A1KMT2A | |
| SCHEMBL25351183 | 0.82 | TP53 (0.69) | TP53LMNAMAPTALDH1A1KMT2A | |
| SCHEMBL25349011 | 0.80 | TP53 (0.67) | TP53LMNAMAPTALDH1A1KMT2A | |
| SCHEMBL25349325 | 0.80 | TP53 (0.75) | TP53LMNAMAPTALDH1A1KMT2A | |
| SCHEMBL25349817 | 0.80 | TP53 (0.69) | TP53LMNAMAPTALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149673-A1 | INHIBITORS OF STORE OPERATED CALCIUM RELEASE | CALCIMEDICA, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149673-A1 | INHIBITORS OF STORE OPERATED CALCIUM RELEASE | CALCIMEDICA, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8143269-B2 | Inhibitors of store operated calcium release | CALCIMEDICA, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143269-B2 | Inhibitors of store operated calcium release | CALCIMEDICA, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100087415-A1 | INHIBITORS OF STORE OPERATED CALCIUM RELEASE | CALCIMEDICA, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087415-A1 | INHIBITORS OF STORE OPERATED CALCIUM RELEASE | CALCIMEDICA, INC. (US) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149673-A1 | INHIBITORS OF STORE OPERATED CALCIUM RELEASE | ORAI1, SARAF, RYR2 | TP53 3849/4885LMNA 1170/4885MAPT 1453/4885 |
| US-20100087415-A1 | INHIBITORS OF STORE OPERATED CALCIUM RELEASE | ORAI1, SARAF, RYR2 | TP53 3849/4885LMNA 1170/4885MAPT 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.